Found: 2
Select item for more details and to access through your institution.
Factors Contributing to the Prognosis after Second-line Therapy with Ramucirumab in Advanced Hepatocellular Carcinoma.
- Published in:
- Internal Medicine, 2022, v. 61, n. 21, p. 3157, doi. 10.2169/internalmedicine.9237-21
- By:
- Publication type:
- Article
Comparison of Efficacy and Safety of Atezolizumab Plus Bevacizumab and Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Propensity Score Matching Analysis.
- Published in:
- Targeted Oncology, 2022, v. 17, n. 6, p. 643, doi. 10.1007/s11523-022-00921-x
- By:
- Publication type:
- Article